The World Health Organization (WHO) has released a new global plan, urging countries to improve their response to the growing risk of fungal diseases and antifungal resistance. The health and disease regulatory body warned that the issue has been left unaddressed since a long time despite its serious impact on public health.WHO Shares Plan To Tackle Fungal Infections & Drug Resistance According to the WHO, fungal diseases affect more than 300 million people worldwide every year. It also said that they are responsible for serious complications, prolonged hospitalisation, and high mortality, particularly among those with weakened immune systems. Despite the risks, fungal infections continue to receive far less attention than bacterial or viral diseases. They are also missing from national health strategy planning, particularly in antimicrobial resistance (AMR) plans. Why Antifungal Resistance Is A Global Concern? Antifungal resistance happens when fungi grow, resisting medicines used to treat the infections. This makes it harder and sometimes impossible to cure infections. The WHO said resistance to antifungal drugs is being fueled by: Uncontrolled use of antifungal medicines not only in human healthcare but also in agriculture and animal health. Excessive environmental exposure to antifungal chemicals continues to accelerate resistance. Health experts have repeatedly warned that resistant fungal infections could become a major public health challenge, as the number of people living with conditions that weaken the immune system, including cancer, HIV, diabetes, and other chronic diseases, continues to rise. Climate change is also believed to be altering the distribution of certain disease-causing fungi, increasing the risk of outbreaks in new regions. Also read: The High Cost of Ignoring Fungi: The Hidden Burden of Invasive Fungal Infections Dr Jean Pierre Nyemazi, Acting Director of WHO's Department of Antimicrobial Resistance said, “The Updated Global Action Plan on AMR approved by the Seventy-ninth World Health Assembly recognized that antifungal resistance is an integral part of the AMR challenge and one we can no longer afford to overlook. This Blueprint gives countries a concrete path forward.” What Does The WHO Blueprint Outline? The blueprint to fight fungal infections has been developed with input from more than 150 experts across WHO regions, including specialists in infectious diseases, diagnostics, surveillance, public health and patient advocacy. It builds on the WHO's fungal priority pathogens list released in 2022, which identified the most dangerous fungal pathogens threatening human health. The guidance outlines four priority areas for countries to strengthen their response. These include: Improving public awareness, infection prevention, and antifungal stewardship programmes. Expanding access to quality diagnostics and effective antifungal medicines while encouraging research and innovation. Strengthening laboratory networks, disease surveillance and outbreak preparedness Addressing environmental and agricultural factors contributing to antifungal resistance. Through a One Health approach that recognises the interconnected health of humans, animals and the environment. The WHO has also identified 12 key areas to help governments prioritise investments and integrate fungal disease surveillance into existing healthcare systems. WHO officials said fungal diseases continue to be neglected across national health policies despite their growing burden. Hatim Sati, Technical Officer in WHO's Department of Antimicrobial Resistance, who led the blueprint's development, said, “Fungal disease and antifungal resistance remain an under-addressed priority across national health plans, AMR strategies, and surveillance systems. This Blueprint provides countries with a practical framework to strengthen their response.”